During a live event, Patrick Hagen, MD, considered the evidence for using teclistamab plus daratumumab in a patient with myeloma relapse after quadruplet induction and transplant.
NCCN now recognizes image-only, mammogram-derived AI as a primary risk tool, shifting risk stratification from ...
At SGO 2026, Alison Schram, MD, highlighted first-in-class tumor suppressor reactivation and emphasized early NGS testing in ...
In an interview with Targeted Oncology, Naomi Haas, MD, discusses the evolving landscape of adjuvant and neoadjuvant immune ...
The FDA has granted fast track designation to OPN-6602, an investigational oral dual inhibitor of EP300 and CREB-binding ...
In an interview during 2026 SGO Annual Meeting, Bradley Monk, MD, spoke about the final results of the phase 3 KEYNOTE-B96 ...
Safety featured universal TEAEs and 92% grade ≥3 events; anemia (39.5%) predominated, discontinuations were frequent, and ...
MSK experts discuss FLAURA2 updates, emerging targets in mesothelioma, and next-gen immunotherapies from the 2026 European ...
Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...
Dr. Nooka provides comprehensive guidance on bispecific antibody safety management, emphasizing the predictable chronology of ...
Dr. Nooka reviews the current approved bispecific antibody landscape, noting that MajesTEC-1, MajesTEC-3, and MonumenTAL-1 ...
Chimeric antigen receptor T-cell therapy (CAR T) has revolutionized oncology treatment over the last decade, offering targeted therapy options for several difficult cancers, espec ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results